NCT06607120View on ClinicalTrials.gov

Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies

RecruitingOBSERVATIONAL
Enrollment

950

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

January 31, 2025

Study Completion Date

March 1, 2025

Conditions
Hepatocellular Carcinoma
Trial Locations (1)

Unknown

RECRUITING

Zhongda Hospital, Nanjing

All Listed Sponsors
lead

Zhongda Hospital

OTHER